Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases

Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases

US Patent 10336741 · Granted Jul 2, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

DNA polymerase theta inhibitor for treatment of cancer2024
Compounds, compositions, and therapeutic uses thereof2024
Dihydroindolizinone derivative2023
Dihydroindolizinone derivative2023
Method for producing bicyclic compound2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembol2021